Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 375 clinical trials
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: ribociclib everolimus dexamethasone

  • 13 views
  • 27 Jan, 2021
  • 9 locations
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in …

  • 7 views
  • 23 Jan, 2021
  • 6 locations
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

monitoring, in treating patients with kidney cancer that is limited to a certain part of the body (localized). Nivolumab is a drug that may help stimulate the immune system to attack any cancer cells that

liver disease
a 12
tubal ligation
antibiotics
hepatitis b surface antigen
  • 351 views
  • 02 Mar, 2021
  • 270 locations
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

fluoropyrimidine
metastasis
metastatic colorectal cancer
modified folfox6 regimen
carcinoma
  • 74 views
  • 02 Mar, 2021
  • 40 locations
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.

pet scan
carcinoma
clear cell renal cell carcinoma
nephrectomy
  • 21 views
  • 28 Feb, 2021
  • 38 locations
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

carcinoma
karnofsky performance status
  • 25 views
  • 17 Feb, 2021
  • 7 locations
Anesthesia and Cancer Study: Renal Cell Carcinoma

This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy. The participants will be allocated to either the group receiving the total intravenous anesthesia (TIVA) using propofol or the group receiving the inhaled anesthetics, such as sevoflurane or desflurane.

cancer
carcinoma
anesthesia
nephrectomy
  • 0 views
  • 25 Jan, 2021
  • 1 location
Renal Adjuvant MultiPle Arm Randomised Trial

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably …

serum pregnancy test
systemic therapy
metastasis
nephrectomy
ct scan
  • 60 views
  • 25 Jan, 2021
  • 35 locations
Open vs Robotic Assisted Partial Nephrectomy

patients with intermediate to high complexity kidney tumors.

nephrectomy
renal neoplasm
  • 0 views
  • 27 Jan, 2021
  • 20 locations
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

advanced renal cell carcinoma
solid tumour
clear cell renal cell carcinoma
vegf
kinase inhibitor
  • 168 views
  • 28 Feb, 2021
  • 147 locations